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234 diagnostic formalin‑fixed paraffin‑embedded (FFPE) blocks from homogeneously treated 
patients with locally advanced head and neck squamous cell carcinoma (HNSCC) within a 
multicentre phase III clinical trial were characterised. The mutational spectrum was examined by 
next generation sequencing in the 26 most frequent oncogenic drivers in cancer and correlated with 
treatment response and survival. Human papillomavirus (HPV) status was measured by p16INK4a 
immunohistochemistry in oropharyngeal tumours. Clinicopathological features and response to 
treatment were measured and compared with the sequencing results. the results indicated TP53 as 
the most mutated gene in locally advanced HNSCC. HPV‑positive oropharyngeal tumours were less 
mutated than HpV‑negative tumours in TP53 (p < 0.01). Mutational and HPV status influences patient 
survival, being mutated or HPV‑negative tumours associated with poor overall survival (p < 0.05). No 
association was found between mutations and clinicopathological features. This study confirmed and 
expanded previously published genomic characterization data in HNSCC. Survival analysis showed 
that non‑mutated HNSCC tumours associated with better prognosis and lack of mutations can be 
identified as an important biomarker in HNSCC. Frequent alterations in PI3K pathway in HPV‑positive 
HNSCC could define a promising pathway for pharmacological intervention in this group of tumours.
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common neoplasia in the developed  world1. 
It constitutes a heterogeneous disease of tumours of the upper aerodigestive tract with different pathogenic ori-
gins and clinical prognosis. Tobacco smoking and alcohol consumption are still the most classical risk  factors2 
followed by viral  infection3,4.
open
1Medical Oncology Service, University Hospital of Salamanca-IBSAL, 37007 Salamanca, 
Spain. 2Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 
37007 Salamanca, Spain. 3Molecular Medicine Unit-IBSAL, Department of Medicine, University of Salamanca, 
37007 Salamanca, Spain. 4Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of 
Salamanca-CSIC, 37007 Salamanca, Spain. 5Medical Oncology Department, Institut Català d’Oncologia, 
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Most HNSCC are diagnosed as locally advanced disease (stage III or IV) and therefore multidisciplinary treat-
ment strategies include surgery, radiotherapy (RT), chemotherapy (CT) and targeted therapy. However, treatment 
with chemoradiotherapy (CTRT) has become the standard of care after the publication of a large pool  analysis5. 
With the aim of improving the clinical benefit, the addition of cetuximab, an IgG1 chimeric monoclonal anti-
body against epidermal growth factor receptor (EGFR), concomitant with RT was explored, resulting in longer 
progression-free survival (PFS) and overall survival (OS) compared to RT alone, although a direct comparison 
with CTRT has not been evaluated  yet6.
The role of induction chemotherapy has remained a subject of controversy. The combination of docetaxel-
cisplatin and 5-fluorouracil (TPF) has emerged as the most active regimen in locally advanced disease, showing 
better results than PF, although it did not show a convincing survival benefit in induction regimens compared 
with historical data of treatment with concomitant chemoradiotherapy  alone7–9. Induction chemotherapy to 
improve organ preservation and survival may be an alternative to CTRT. The addition of cetuximab to radiation 
therapy in patients with laryngeal cancer stage III and IVA that respond to TPF could improve functional laryn-
geal  preservation10, although randomized phase III trials did not find that induction chemotherapy provided 
benefit in time-to-treatment failure or  OS11–14. On the other hand, a randomized phase II–III study suggested 
that adding TPF induction chemotherapy to CTRT resulted in a higher rate of radiological complete response 
compared with concurrent CTRT alone, improving PFS and OS by induction  TPF15. The fact that patient popula-
tions in these trials were very heterogeneous, questions induction chemotherapy’s benefit thus, subgroups that 
will have a benefit from it need to be identified.
Next-generation sequencing (NGS) has helped to identify genetic alterations that could be used as a molecular 
vulnerability for therapeutic discovery and target optimization. In addition, they could have a prognosis utility 
as biomarkers of response in different tumour types including head and neck squamous cell  carcinomas16,17. For 
instance, the analysis of The Cancer Genome Atlas (TCGA) described the molecular landscape of HPV-positive 
and HPV-negative HNSCC as having molecular alterations not reported  before18. Since the first description of 
the recurrently mutated genes in  HNSCC19, additional studies have included other genes such as TP53, NOTCH1, 
PIK3CA, CDKN2A, CCDN1, HRAS, FAT1, FBXW7 and FGFR3, among  others20,21. For this reason, targeted 
sequencing has become a flexible tool to study those genes previously reported as mutated in  HNSCC21.
To contribute to the understanding of how somatic mutations influence the outcome of HNSCC treatment, 
we have studied a panel of 26 genes (Table S1) by next-generation sequencing in a homogenously treated locally 
advanced HNSCC Spanish cohort. In this study we report some mutations linked with detrimental outcome and 
their presence in relation to HPV presence.
Results
cohort characteristics. 234 FFPE blocks with diagnostic biopsies from HNSCC patients within a multi-
centre phase III clinical trial were incorporated in this study (Fig. S1). Clinical demographic factors such as age, 
gender, disease site and tumour stage are consistent between the whole cohort within the clinical trial and the 
subsequent random selection due to FFPE block availability in this study. Overall, most were from men (89.7%), 
with pharyngeal carcinoma (65.4%) and diagnosed in tumour stage IV-A (71.4%) with an average of 57 years old 
(Table 1). Clinicopathologic features by locations are shown in Table 1.
Considering only oropharyngeal tumours (see “Methods” section), 13 samples (17.1%) were HPV-positive 
based on p16 immunohistochemistry (IHC). According to its grade, HPV-positive samples were statistically 
associated with poorly differentiated (p = 0.016) and TP53 wild-type (p = 0.009) tumours (Table 2).
Targeted panel sequencing in HNSCC FFPE blocks identified 162 samples (69.23%) with previously described 
pathogenic mutations whereas 46 (19.66%) did not carry any mutation and 26 (11.11%) showed variants of 
uncertain clinical significance (VUS). 194 pathogenic mutations and 72 VUS were found in the sequencing of 
the 234 FFPE blocks. All samples were sequenced > 5000 × (7074 ± 10,516). Globally, the most mutated gene 
was TP53 (61.1%) followed by PIK3CA (10.3%), FBXW7 (1.7%), PTEN (1.3%) and CKIT and CTNNB1 (both 
with 0.43%) (Fig. 1). 144 out of 162 (88.89%) mutated tumours had TP53 mutations either alone or with others. 
Most of the pathogenic variants were missense (55.67%), followed by stop-gained (18.04%), frameshift (14.95%), 
splice-donor (8.76%) and in-frame deletions (2.58%) (Table S2).
Association of mutations with clinical variables. General comparison of the mutational status and 
tumour characteristics such as location, grade and histology, did not show any significant difference (p > 0.05) 
(Table 3). However, considering variants of uncertain significance, women were associated with a lower percent-
age of mutation than men in our cohort (p = 0.002) (Table 3).
Mutational profile and HPV presence in oropharyngeal tumours. HPV mutational profile in oro-
pharyngeal tumours is shown in Fig. 2. HPV-positive samples presented slightly more pathogenic mutations 
than HPV-negative (76.2% versus 69.2%, p = 0.762) (Table 2). Despite the fact that TP53 was the most frequently 
mutated gene in both groups, these mutations were more recurrent in HPV-negative tumours (71.4% in HPV-
negative and 30.8% in HPV-positive), difference statistically significant (p = 0.009). Conversely, the second most 
mutated gene, PIK3CA, although more represented in HPV-positive tumours (9.5% in HPV-negative versus 
23.1% in HPV-positive), did not show any statistically significant difference (p = 0.178). While HPV-negative 
tumours did not present pathogenic mutations in other genes, PTEN was the third most commonly mutated in 
HPV-positive tumours (15.4%), followed by FBXW7 (7.7%).
Mutational status and response to treatment. After induction chemotherapy, 188 (80.34%) patients 
were similarly randomized: 95 (50.53%) to conventional treatment and 93 (49.47%) to the experimental arm. 
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Preliminary data indicated that the two regimens showed similar survival, response rates, toxicity and locore-
gional  control22. For that reason, both arms were evaluated within the same group as final response (or response 
after randomization). Evaluation of the two time-point responses according to the mutational profile did not 
show any statistical difference (Table 4). There was, however, a tendency between mutated tumours and complete 
response at the end of the treatment taking VUS into consideration, p = 0.096 (Table S3).
Considering only HPV profile in oropharyngeal tumours, there were no differences between HPV-positive 
and HPV-negative individuals either after induction chemotherapy (p = 0.396) or randomization (p = 0.914) 
(Table 5).
Finally, an exploratory analysis was performed using the two most mutated genes in the study: TP53 and 
PIK3CA (Table S4). Analysing patients with mutations in those genes alone or within other genes and the clini-
cal response, indicated that none of the TP53 subgroups were associated in any of the clinical trial treatment 
timepoints (p > 0.05). By contrast, considering only PIK3CA mutations, a statistically positive association was 
found in the complete response group after induction chemotherapy (p = 0.024). However, this finding was not 
corroborated in final response group (p = 0.235) (Table S4) what could suggest that this could be a false positive 
result taken into consideration multiple testing and sample size bias.
Poeta’s23 and Neskey’s24 classification in patients harbouring TP53 mutations in relation with clinical response 
before and after randomization did not show any statistically significant association (p > 0.05, Table S5).
HPV, mutational status and clinical outcome. HPV-positive oropharyngeal tumours showed higher 
OS compared with HPV-negative (p = 0.044). This tendency was also shown in PFS, however, without statisti-
cally significant results (p = 0.148, HR = 0.498 (0.194–1.280)) (Fig. 3A,B).
Moreover, OS was correlated with the mutational status. Patients without mutations in the selected genes had 
a better OS than patients with mutated tumours (p = 0.011, HR = 1.672 (1.123–2.491)) (Fig. 3C). This difference 
was also observed in PFS without statistically significant results (p = 0.135, HR = 1.349 (0.911–1.999)) (Fig. 3D).
A correlation with the number of mutations also showed that tumours with one mutation had lower OS 
(p = 0.038, HR = 1.544 (1.025–2.327)) than non-mutated patients, with the exception of PFS (p = 0.259, HR = 1.264 
(0.842–1.898)) (Fig. 3E,F). Equally, tumours with more than one mutation showed lower OS (p = 0.001, 
Table 1.  Clinicopathologic characteristic of the 234 HNSCC patients included in the study: overall and by 





Oropharynx Hypopharynx Larynx Oral cavity
N (%) N (%) N (%) N (%)
234 (100) 90 (38.5) 63 (26.9) 41 (17.5) 40(17.1)
Age (years ± SD) 57.42 ± 6.9 59.46 ± 6.7 56.61 ± 8.1 58.34 ± 5.7 57.55 ± 6.9
Sex
Man 209 (89.7) 76 (36.4) 59 (28.2) 40 (19.1) 34 (16.3)
Woman 24 (10.3) 14 (58.3) 3 (12.5) 1 (4.2) 6 (25.0)
Unk 1 0 1 0 0
TNM
III 20 (8.7) 11 (55.0) 1 (5.0) 4 (20.0) 4 (20.0)
IVA 165 (71.4) 64 (38.8) 43 (26.1) 29 (17.6) 29 (17.6)
IVB 46 (19.9) 15 (32.6) 17 (37.0) 8 (17.4) 6 (13.0)
Unk 3 0 2 0 1
Grade
Well differentiated 32 (15.1) 13 (40.6) 8 (25.0) 3 (9.4) 8 (25.0)
Moderately differentiated 102 (48.1) 41 (40.2) 15 (14.7) 27 (26.5) 19 (18.6)
Poorly differentiated 78 (36.8) 28 (35.9) 32 (41.0) 9 (11.5) 9 (11.5)
Unk 22 8 8 2 4
Histology
Keratinizing 94 (48.0) 40 (42.6) 19 (20.2) 13 (13.8) 22 (23.4)
Non-keratinizing 100 (51.0) 36 (36.0) 31 (31.0) 25 (25.0) 8 (8.0)
Undifferentiated 2 (1.0) 1 (50.0) 0 (0) 0 (0) 1 (50.0)
Unk 38 13 13 3 9
HPV
Positive 13 (6.7) 13 (100.0) 0 (0) 0 (0) 0 (0)
Negative 182 (93.3) 63 (34.6) 50 (27.5) 38 (20.9) 31 (17.0)
Unk 39 14 13 3 9
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Table 2.  HPV association in oropharyngeal tumours with clinicopathological characteristics. TNM 
classification system stands for tumour, node and metastasis. HPV status based on p16 + IHC could only be 
measured in 76 (84.4%) out of the 90 oropharyngeal tumour samples. SD standard deviation, Unk unknown. 




N (%) N (%)
63 (82.9) 13 (17.1)
Age (years ± SD) 57.08 (7.11) 58.46 (6.40) 0.562*1
Sex
Man 55 (84.6) 10 (15.4) 0.388*2
Woman 8 (72.7) 3 (27.3)
TNM
III 5 (71.4) 2 (28.6) 0.166*3
IVA 45 (80.4) 11 (19.6)
IVB 13 (100.0) 0 (0.0)
Grade
Well differentiated 10 (83.3) 2 (16.7) 0.016*3
Moderately differentiated 36 (94.7) 2 (5.3)
Poorly differentiated 16 (64.0) 9 (36.0)
Histology
Keratinizing 36 (90.0) 4 (10.0) 0.177*3
Non-keratinizing 26 (74.3) 9 (25.7)
Undifferentiated 1 (100.0) 0 (0.0)
Mutational status
Non-mutated 15 (78.9) 4 (21.1) 0.726*2
Mutated 48 (84.2) 9 (15.8)
TP53 mutated
Non-mutated 18 (66.7) 9 (33.3) 0.009*2
Mutated 45 (91.8) 4 (8.2)
PIK3CA mutated
Non-mutated 57 (85.1) 10 (14.9) 0.178*2
Mutated 6 (66.7) 3 (33.3)
Figure 1.  Number of mutations found in the sequencing of 234 HNSCC by TruSight Tumor 26 panel. Blue bars 
represent pathogenic mutations while orange bars show variants of uncertain significance (VUS).
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HR = 2.524 (1.441–4.422)) and PFS (p = 0.036, HR = 1.824 (1.039–3.203)) than non-mutated samples. Conversely, 
the differences between tumours with one or more mutations were not statistically significant (p > 0.05).
Finally, we compared TP53 mutations based on Poeta’s23 and Neskey’s24 stratification models with OS and 
PFS (Fig. S2). No association was observed between low-risk/high risk mutations or non-disruptive/disruptive 
mutations and survival in these patients (Fig. S2).
Discussion
As most of the head and neck cancers are diagnosed at a locally advanced stage the identification of biomarkers 
of response is a main goal to optimize treatment and reduce side effects. In recent years, induction chemotherapy 
has been shown to produce a benefit in organ preservation without a clear improvement in survival. In addition, 
this approach led to a high toxicity, particularly when concurrent radiotherapy was given with high doses of 
cisplatin. At present, very few predictive biomarkers of response have been described. For this reason, we pro-
posed a study of the mutational status in 26 of the most common altered genes in cancer with next-generation 
sequencing in a homogeneously treated representative Spanish cohort of HNSCC from the phase III clinical 
trial TTCC-2007-0122.
The epidemiology characteristics of the HNSCC patients included in our study were similar to other series 
reported from the same region: the ratio between sexes is 9:1 in detriment of men, and most of the patients were 
diagnosed at stage  IV25. p16 IHC, a surrogate of HPV infection in oropharyngeal tumours, showed that HPV was 
present in 17.1% of samples, a lower percentage than previously reported in  Europe26 but with similar location 
to other Southern European countries in  oropharynx27.
Globally, the most mutated gene in our series was TP53 (61.1%). We observed a statistically significant lower 
percentage of mutated TP53 in HPV-positive oropharyngeal tumours (71.4%) than in HPV-negative (30.8%) as 
has been previously reported in  HNSCC28,29. These results could be explained if TP53 sequestration by the viral 
oncoprotein E6 prevents gaining mutations in this gene under selective pressure  of30,31. Comparing to other series, 
there was a higher percentage of TP53 mutations in HPV-positive  tumours29. This fact could be explained by the 
coexistence of viral infection and other aetiological factors such as tobacco smoking and alcohol consumption 
Table 3.  Association between mutational status and clinicopathological characteristics. TNM classification 
system stands for tumour, node and metastasis. SD standard deviation, Unk unknown. a Initially, statistical 
analysis was done comparing normal, pathogenic mutation and variants of uncertain clinical significance 
(VUS), p-value. b To avoid bias with VUS, a direct comparison only between normal and pathogenic mutation 
was done, p-value. *Variant of uncertain clinical significance. *1Kruskal–Wallis H test. *2Fisher’s exact test. 
*3Chi-square test.
Variable
Normal Pathogenic VUS* p-valuea p-valueb
N (%) N (%) N (%) All
Normal vs mutant46 (19.66) 162 (69.23) 26 (11.11)
Age (years ± SD) 57.02 (7.65) 57.68 (6.95) 56.44 (6.50) 0.683*1 0.941*1
Sex
Man 39 (18.7) 152 (72.7) 18 (8.6) 0.002*2 0.290*2
Woman 7 (29.2) 10 (41.7) 7 (29.2)
Unk 0 0 1
TNM
III 5 (25.0) 13 (65.0) 2 (10.0) 0.777*2 0.781*2
IVA 32 (19.4) 113 (68.5) 20 (12.1)
IVB 8 (17.4) 35 (76.1) 3 (6.5)
Unk 1 1 1
Location
Oropharynx 16 (17.8) 66 (73.3) 8 (8.9) 0.644*2 0.582*2
Hypopharynx 14 (22.2) 43 (68.3) 6 (9.5)
Larynx 8 (19.5) 29 (70.7) 4 (9.8)
Oral cavity 8 (20.0) 24 (60.0) 8 (20.0)
Grade
Well differentiated 7 (21.9) 24 (75.0) 1 (3.1) 0.578*2 0.588*2
Moderately differentiated 17 (16.7) 73 (71.6) 12 (11.7)
Poorly differentiated 17 (21.8) 52 (66.7) 9 (11.5)
Unk 5 13 4
Histology
Keratinizing 14 (14.9) 72 (76.6) 8 (8.5) 0.346*2 0.652*2
Non-keratinizing 21 (21.0) 67 (67.0) 12 (12.0)
Undifferentiated 1(50.0) 1(50.0) 0 (0.0)
Unk 10 22 6
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Figure 2.  Mutational landscape plot divided into HPV-negative (left) and HPV-positive (right) oropharyngeal 
tumours. Legend represents different colours according to its clinical features. Percentage of pathogenic 
mutations in each gene is indicated at the edges by their HPV profile.
Table 4.  Association between mutational status and response after induction and randomization (final 
response), without VUS. p-value significant if p < 0.05 and size effect indicated by the odd ratio (OR) with 95% 




OR 95% CI p-valueN (%) N (%)
Response after induction 37 (21.5) 135 (78.5)
Complete 5 (13.5) 19 (14.1) 0.954 0.330–2.753 0.931
Partial/stabilization 32 (86.5) 116 (85.9)
Final response 21 (17.9) 96 (82.1)
Complete 13 (61.9) 61 (63.5) 0.932 0.352–2.469 0.888
Partial/stabilization 8 (38.1) 35 (36.5)
Table 5.  Association between HPV status and response after induction and randomization (final response). 
p-value significant if p < 0.05 and size effect indicated by the odd ratio (OR) with 95% confidence interval 
(CI). From initial 76 oropharyngeal tumours with HPV determination, 65 (85.5%) of them were evaluable for 
response after induction and 42 (55.3%) for final response.
Variable
HPV-negative HPV-positive
OR 95% CI p-valueN (%) N (%)
Response after induction 52 (80.0) 13 (20.0)
Complete 7 (70.0) 3 (30.0) 0.519 0.114–2.362 0.396
Partial/stabilization 45 (81.8) 10 (18.2)
Final response 33 (78.6) 9 (21.4)
Complete 19 (79.2) 5 (20.8) 1.086 0.246–4.793 0.914
Partial/stabilization 14 (77.8) 4 (22.2)
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Figure 3.  Kaplan–Meier survival curves. HPV status in oropharyngeal tumours and overall survival (OS) (A) 
and progression free survival (PFS) (B), mutational status in all the samples and OS (C) and PFS (D), number of 
mutations in all the samples and their OS (E) and PFS (F). Median with 95% confidence interval (CI), log rank 
test p-values and hazard ratios (HR) with 95% CI, are shown in each plot.
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during  tumourigenesis32; these data were not collected in this study. TCGA data described 85% of TP53 muta-
tion in HPV-negative tumours and only 3% in HPV-positive  ones18. However, the sample population was very 
different with a high predominance of oral cavity tumours (62%) and mainly heavy smokers.
PI3K/AKT/mTOR has been reported as the most mutated pathway in HNSCC (13% to 56%), regardless 
of the HPV  status18. PIK3CA gene, that encodes the catalytic subunit of the family, has been reported with an 
average mutational rate of 10.53% in  HNSCC33, similar to the 10.25% found in this cohort, and with a higher 
frequency in laryngeal  tumours34. Mutations in this gene have also been related to HPV-positive  tumours4. Our 
results corroborate this fact, being PIK3CA more frequently mutated in HPV-positive tumours (23.1% versus 
9.5% in HPV-negative oropharyngeal tumours), similar to previously described  data35. We did not, however, 
see an increased percentage in laryngeal carcinoma. 73% of the mutations in PIK3CA are commonly located in 
3 hotspots (E542K, E545K and H1047R/L)36, result also found in 76% of PIK3CA mutated samples in our study, 
emphasising the accuracy of using the targeted panel in HNSCC.
Mutations in FBXW7: an E3 ubiquitin ligase member of the F-box protein family, have been previously 
observed in  HNSCC19. This tumour suppressor gene targets NOTCH1, being an important protein in cell pro-
liferation control. Previous studies found FBXW7 mutated in 5% of  HNSCC37,38 and a higher percentage of 
mutations was previously considered as a prevalent event in HPV-positive  tumours39. Our cohort confirmed 
these results in FBXW7 with a similar percentage only found in HPV-positive tumours (7.7%).
PTEN was the third most mutated gene in 15.4% of the HPV-positive oropharyngeal tumours while not muta-
tions were found in HPV-negative ones. Contrary to our results, TCGA study showed PTEN mutated in 12% 
of HPV-negative tumours and 6% of HPV-positive18. Apart from PTEN, there were other genes which mutated 
at a lower percentage in our series, such as CKIT or CTNNB1 (both mutated at less than 1% and only in non-
oropharyngeal HPV-negative tumours), have been reported in HNSCC in varied  percentages30,38,40. Together 
with PIK3CA, our result enhances the hypothesis of higher prevalence of PI3K pathway activated mutations in 
HPV-positive  tumours41.
Overall, excluding TP53 mutations, recurrent alterations in PIK3CA, PTEN and FBXW7 genes, all belong-
ing to the PI3K/AKT/mTOR pathway, could define a potential new target for pharmacological intervention in 
HNSCC, as it has been suggested in other  publications42.
In terms of survival, HPV-positive oropharyngeal tumours were associated with better prognosis, showing 
an increased OS and PFS compared to HPV-negative tumours as it was previously  defined26,43–47. Secondly, the 
presence of mutation in the targeted genes was associated with inferior outcome demonstrated by the presence 
of detrimental OS. These results could be an indirect measure of tumour aggressiveness, as has been reported 
in other  series43,47. Moreover, the fact that carriers of tumours with more than one mutation have lower OS than 
those with non-mutated tumours reinforces this concept.
Lastly, there was a lack of association between mutational status and response after treatment. This can 
indicate that, excluding genetic-driven druggable targets, HNSCC mutational profile is not related to any clini-
cal response but is a matter of mutational burden as is shown in the survival analyses. Similarly, there was no 
association between TP53 mutations stratified by Poeta’s23 and Neskey’s  models24 and response to treatment or 
survival. These classification systems can serve as an important tool in individualizing and improving treatment 
for high TP53 mutated tumours, as it was previously identified in a subset of high-risk patients with a decreased 
response to platinum-based  therapies48. Nevertheless, these classification models did not have any implication 
on outcome in our cohort.
Overall, our data strongly support and expand previously published studies exploring the presence and 
prognosis of mutations in this population. We have characterized the mutational profile of HPV-positive/HPV-
negative oropharyngeal HNSCC in a representative cohort of patients. In this context apart from TP53 mutations, 
frequent alterations in PIK3CA, PTEN and FBXW7 genes, define possible pathways for pharmacological interven-
tion. Finally, survival analysis showed that mutational status in the tumour could define patient prognosis, and 
may potentially be used as biomarkers to stratify patients for more intensive treatment. However, larger studies 
should be performed to confirm these results aiming at stratifying patients to different therapeutic interventions.
Methods
Samples. 234 FFPE blocks with diagnostic biopsies from HNSCC patients were included in this study. A 
consort diagram reporting the dropout is shown in Fig. S1. All samples belong to the clinical trial TTCC-2007-
01 entitled: “Open label randomized, multi-centre phase III trial of TPF plus concomitant treatment with cispl-
atin and radiotherapy versus concomitant cetuximab and radiotherapy in locally advanced, unresectable head 
and neck cancer”, ClinicalTrials.gov identifier:  NCT0071639122.
TTCC‑2007‑01 trial design and data collection. It was a non-inferiority, randomized and controlled 
study with a parallel assignment intervention model and an endpoint of safety/efficacy, carried out between 
2008 and 2013. The follow-up of the clinical trial finished in November 2016. According to protocol, written 
informed consent was obtained from living subjects and the protocol was approved by the University Hospital 
of Salamanca and the ethical committees of each hospital in accordance with the 1964 Helsinki declaration and 
its later amendments.
Eligible patients: histologically or cytologically confirmed, previously untreated unresectable locally advanced 
(Stage III–IV) tumours (from oral cavity, oropharynx, larynx, hypopharynx), ECOG performance status 0–1. 
Unresectable disease was determined by Northern California Oncology Group in measurable disease. Treat-
ment: docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy (T 75 mg/m2 d1, P 75 mg/m2 
d1, F 750 mg/m2 CI d 1–5 q 21 d + G-CSF & ciprofloxacin, by 3 cycles; then, if objective response achieved, they 
were randomized to: conventional radiotherapy (RT) up to 70 Gy + P 100 mg/m2 d 1–22–43 vs conventional 
9
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16634  | https://doi.org/10.1038/s41598-020-72927-2
www.nature.com/scientificreports/
RT up to 70 Gy + cetuximab 400/250 mg/m2 weekly until the completion of RT, and they were stratified by pri-
mary tumour site. Surgery after RT (neck dissection) was allowed. The primary endpoint was non-inferiority of 
cetuximab-radiotherapy versus cisplatin-radiotherapy in terms of overall survival. Response rate, loco-regional 
control and toxicity in both arms were considered secondary objectives. Preliminary data of this trial did not 
show any difference in terms of survival or response rates, toxicity and loco-regional control as secondary end 
points in the two  regimens22.
Clinical data were compiled in a case report form by medical oncologists involved in the clinical trial. All data 
were treated with the security measures established in compliance with the Protection of Personal Data Organic 
Law 15/1999, 13th December, and safe-keeping at the University Hospital of Salamanca in its specific server.
DNA extraction. Percentage of tumour cells was measured in haematoxylin–eosin tissue sections by central 
pathologist. Between four and ten 10 µm FFPE sections from diagnosis blocks were treated with deparaffiniza-
tion solution (Qiagen, Hilden, Germany) and DNA extraction was done using QIAamp DNA FFPE Tissue kit 
(Qiagen, Hilden, Germany).
DNA quality evaluation and targeted NGS. Following TruSight Tumor 26 Reference Guide (Illumina, 
San Diego, USA), DNA quality was measured by qPCR. Comparing FFPE-gDNA amplification potential with 
a reference non-FFPE gDNA (QCT), delta Cq value was used to predict the dilution required for each sample.
TruSight Tumor 26 panel includes a set of 174 amplicons in complete exons of 26 cancer-associated genes 
(Table S1). This panel was selected due to its exceptional success rate using minimal DNA input even from 
FFPE samples where genetic material is often degraded. Following steps of hybridization with the oligo pool, 
removing unbound oligos and extension and ligation with bound oligos, an amplification of the libraries were 
performed. PCR products were checked on a 4% TBE agarose gel and finally the libraries were cleaned up by 
AMPure XP magnetic beads (Beckman Coulter, Brea, CA, USA). PCR products were quantified using Qubit 
Fluorometer (Invitrogen, Carlsbad, CA, USA) and libraries were normalized at 4 nM in a final pool. Sequencing 
was performed in a NextSeq 500 System (Illumina, San Diego, USA).
Data were transformed in BaseSpace platform and the VCF file format were read in the Variant Studio Soft-
ware (Illumina, San Diego, USA). Following Illumina recommendations, somatic variants over 5% of frequency, 
with yields at least 1000 × cumulative coverage between the 2 strands and considered from the software of PASS 
filter were reported. Those variants of uncertain significance were considered pathogenic if at least two in silico 
prediction tools (SIFT and PolyPhen) classified them as deleterious/probably  damaging49, and they were defined 
as likely pathogenic in the Catalogue Of Somatic Mutations in Cancer (COSMIC; https ://cance r.sange r.ac.uk/
cosmi c) or the National Center for Biotechnology Information (NCBI; https ://www.ncbi.nlm.nih.gov/clinv ar) 
databases.
Assessment of HpV status. In the original study protocol, the assessment of HPV status was carried out 
by p16 immunohistochemistry (IHC), a surrogate marker for HPV  infection50 as the gold-standard technique. 
FFPE sections were deparaffinized and exposed to 10 mM citrate buffer antigen retrieval at 92 °C for 30 min 
and then they were stained using a  p16INK4a mouse monoclonal antibody (Cell Marque, Rocklin, CA, USA). 
Percentage of p16 staining was measured and only those tumours > 70% nuclear and cytoplasmic p16+ were 
considered positive. 33 samples were considered HPV-positive following this methodology: 13 oropharyngeal, 4 
hypopharyngeal, 2 laryngeal and 9 oral cavity tumours. However, after the publication of the guidelines from the 
college of American pathologists, p16 IHC is only recommended in oropharyngeal tumours but other locations, 
where DNA/RNA viral determination should be performed as a confirmatory  test51. Since there was not more 
DNA from all the samples after the library preparation, only oropharyngeal tumours with > 70% p16 positive 
staining were considered HPV-positive.
Statistical analyses. Statistical analysis compared categorical parameters and mutational status by the 
Chi-square or Fisher’s exact tests; while in continuous nonparametric variables, the Mann–Whitney U or 
Kruskal–Wallis H tests were used. p-values were calculated excluding missing values and they were considered 
statistically significant when p < 0.05. Significant variables were included in the logistic regression analysis and 
size effects were indicated by odds ratio (OR) with their 95% confidence interval (95% CI). Mutational status was 
classified as presence or absence of mutations, number of mutations (none, one or more than one) and the status 
of TP53 and PIK3CA (mutant or wild-type). Response was divided in two groups of treatment: after induction 
chemotherapy and after chemo/cetuximab plus radiotherapy (final response) due to the similar outcome in both 
 arms22. Response was classified in both groups as complete response versus partial response/stabilization. No 
progressions were shown in the cohort.
Survival analysis was done according to the overall survival (OS) and progression-free survival (PFS) by 
Kaplan–Meier plots and log-rank test p-values were calculated in all the curves. Median was indicated in those 
plots in which it was achieved. Hazard-ratio was calculated to measure the risk of the event with its 95% con-
fidence interval (95% CI) by Cox regression. Median follow-up in OS was 32.23 months while in PFS it was 
15.31 months.
Due to high prevalence in TP53 mutations, we applied Poeta’s and Neskey’s classifications stratifying the 
mutations according to its change and functional effect, allowing a better comprehensive understanding on their 
relevance in clinical outcome. Following Poeta’s  classification23, TP53 mutations were divided in two categories: 
disruptive and non-disruptive according to their functional effects on the p53 protein. Additionally, according to 
Neskey’s  model24, also named as Evolutionary Action score of TP53-coding variants (EAp53), missense mutations 
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were stratified into high-risk and low-risk through an in-silico scoring (https ://mammo th.bcm.tmc.edu/EAp53 /). 
Then, comparative analysis was performed in response to treatment, OS and PFS.
All these tests were conducted using SPSS software version 21.0 (SPSS Inc., Chicago) and GraphPad Prism 
software version 6.0 (GraphPad Software Inc., California).
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